Insmed Inc Revenue Growth Rates (INSM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Insmed Inc  (NASDAQ: INSM)
 

INSM's Revenue Growth by Quarter and Year

Insmed Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INSM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 425.49
1st Quarter March 285.88
FY 711.37

INSMs Annual Revenue
Insmed Inc's Revenue in the fiscal year 2025 $ 522.63 millions
Insmed Inc's Revenue in the fiscal year 2024 $ 278.56 millions
Insmed Inc's Revenue in the fiscal year 2023 $ 305.53 millions
Insmed Inc's Revenue in the fiscal year 2022 $ 243.83 millions
Insmed Inc's Revenue in the fiscal year 2021 $ 188.46 millions




INSM Revenue second quarter 2026 Y/Y Growth Comment
Insmed Inc showed record Revenue surge in the second quarter 2026 with 393.78% from the second quarter 2026 2025, to $ 425.49 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue growth. While Insmed Inc' s Revenue doubling of 393.78% ranks overall at the positon no. 90 in the second quarter 2026.


INSM Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 287.82 % -26.78 % 48.28 %
3rd Quarter September - 77.99 % -11.89 % 14.82 %
2nd Quarter June 393.78 % 24.06 % -11.41 % 20.22 %
1st Quarter March 301.24 % -8.49 % 22.27 % 19.9 %
FY   - 87.61 % -8.82 % -

Financial Statements
Insmed Inc's second quarter 2026 Revenue $ 425.49 millions INSM's Income Statement
Insmed Inc's second quarter 2025 Revenue $ 86.17 millions Quarterly INSM's Income Statement


INSM Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 99.44 % -8.46 % 10.15 %
3rd Quarter September - 41.53 % -1.35 % -0.82 %
2nd Quarter June 48.83 % 20.94 % -10.79 % 23.13 %
1st Quarter March 17.53 % 13.6 % -9.11 % 10.23 %
FY (Year on Year)   - 87.61 % -8.82 % -


Back to INSM Growth rate Comparisons >> Back to INSM Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #30
Overall #90

Revenue Y/Y Growth Statistics
High Average Low
393.78 % 31.09 % -100 %
(Jun 30 2026)   (Mar 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #30
Overall #90
Revenue Y/Y Growth Statistics
High Average Low
393.78 % 31.09 % -100 %
(Jun 30 2026)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Insmed Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
222.53 % 8.64 % -100 %
(Dec 31 2011)  


INSM's II. Quarter Q/Q Revenue Comment
Insmed Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 48.83%, to $ 425.49 millions, from $285.88 millions in the first quarter.
INSM is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Insmed Inc's Revenue growth quarter on quarter, overall rank is 244.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #244
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #244
Revenue Q/Q Growth Statistics
High Average Low
222.53 % 8.64 % -100 %
(Dec 31 2011)  


INSM's II. Quarter Q/Q Revenue Comment
Insmed Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 48.83%, to $ 425.49 millions, from $285.88 millions in the first quarter.
INSM is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Insmed Inc's Revenue growth quarter on quarter, overall rank is 244.


Insmed Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,076.57 $ 737.26 $ 522.63 $ 342.10 $ 288.66
Y / Y Revenue Growth (TTM) 272.95 % 171.1 % 87.62 % 13.47 % -7.11 %
Year on Year Revenue Growth Overall Ranking # 3102 # 2724 # 1786 # 267 # 665
Seqeuential Revenue Change (TTM) 46.02 % 41.07 % 52.77 % 18.51 % 6.15 %
Seq. Revenue Growth (TTM) Overall Ranking # 1946 # 2342 # 1759 # 627 # 2113


Cumulative Revenue growth Comment
With 272.95% annual Revenue growth, Insmed Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 419 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2724 to 3102.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 420
Overall # 3102

Revenue TTM Y/Y Growth Statistics
High Average Low
272.95 %
 37.13 %
-14.94 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 100
Sector # 301
S&P 500 # 1946
Cumulative Revenue growth Comment
With 272.95% annual Revenue growth, Insmed Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 419 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2724 to 3102.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 420
Overall # 3102

Revenue TTM Y/Y Growth Statistics
High Average Low
272.95 %
37.13 %
-14.94 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 100
Sector # 301
S&P 500 # 1946




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INSM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions


About Insmed Inc Revenue Growth Rates (INSM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Insmed Inc (CIK 1104506).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104506-26-000041
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Insmed Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.